Loading...
XTSE
EDT
Market cap265mUSD
Dec 05, Last price  
1.27CAD
1D
0.00%
1Q
-22.09%
Jan 2017
361.82%
Name

Spectral Medical Inc

Chart & Performance

D1W1MN
XTSE:EDT chart
P/E
—
P/S
160.63
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.48%
Rev. gr., 5y
-4.43%
Revenues
2m
+43.05%
7,272,0002,169,0002,993,0003,011,0003,283,0002,821,0002,539,0002,589,0002,672,0002,964,0003,089,0003,545,0003,806,0003,840,0002,868,0002,101,0002,052,0001,667,0001,598,0002,286,000
Net income
-15m
L-1.66%
-4,655,0003,730,000-1,666,000-1,502,000-2,764,000-6,567,000-6,713,000-8,543,000-11,307,000-9,492,000-9,524,000-10,149,000-3,939,000-2,489,000-4,868,000-8,982,000-8,720,000-11,299,000-15,662,000-15,402,000
CFO
-9m
L-17.75%
-4,209,000-1,270,000-732,000-523,000-1,108,000-4,477,000-6,273,000-7,725,000-9,191,000-10,008,000-9,136,000-11,125,000-3,595,000-2,322,000-2,738,000-324,000-8,701,000-9,928,000-10,721,000-8,818,000
Dividend
Dec 19, 20110.12 CAD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
URL
https://spectraldx.com/
IPO date
Jul 16, 1992
Employees
32
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT